Hyperpolarized NMR Reveals Real-Time Metabolic Dynamics in CAR T Cell Manufacturing
Key Insights
Researchers developed hyperpolarized [U-13C,2H]glucose NMR spectroscopy to measure real-time glycolytic flux in CAR T cells during manufacturing, revealing a 30-fold increase in metabolic activity from day 1 to day 7 of expansion.
The study identified critical nutrient depletion patterns during CAR T cell manufacturing, with glucose becoming nearly completely depleted within the first 10 days and amino acids being extensively consumed during early expansion phases.
Metabolic profiling showed CAR T cells transition from oxidative phosphorylation to aerobic glycolysis during activation, then shift back toward oxidative metabolism by day 21, providing insights for optimizing manufacturing protocols.
Researchers have developed a novel approach using hyperpolarized nuclear magnetic resonance (NMR) spectroscopy to monitor real-time metabolic changes in CAR T cells during manufacturing, potentially improving the quality and effectiveness of these cancer immunotherapies. The study, published in Scientific Reports, demonstrates how advanced metabolic imaging can provide critical insights into CAR T cell function during the crucial expansion phase.
Revolutionary Metabolic Monitoring Technology
The research team established hyperpolarized [U-13C,2H]glucose as a non-invasive molecular marker for measuring glycolytic flux in CAR T cells. This technique provides five orders of magnitude signal enhancement compared to standard NMR methods, enabling real-time monitoring of metabolic conversion for approximately two minutes.
"Hyperpolarized [U-13C,2H]glucose provided similar signal to noise for the product, this substrate was chosen for further metabolic studies as it was desirable to measure flux from the full glycolysis and not only the last enzymatic step," the researchers explained.
The method revealed dramatic metabolic changes during CAR T cell expansion, with glycolytic flux increasing more than 30-fold from day 1 to day 7, when metabolic activity peaked. By day 21, glycolytic activity had decreased significantly, indicating a metabolic shift back toward oxidative phosphorylation.
Critical Nutrient Depletion Identified
The study uncovered significant nutrient limitations during standard CAR T cell manufacturing protocols. Analysis of cell culture media revealed near-complete glucose depletion within the first 10 days of expansion, with consumption dropping from 88% to 17% of available glucose between days 10 and 12.
"The near-complete depletion of glucose and substantial consumption of amino acids within the first 10 days underscore the importance of ensuring sufficient nutrient availability during early culture stages to support optimal cell growth and function," the researchers noted.
All amino acids present in the growth medium, including arginine, cysteine, histidine, isoleucine, leucine, phenylalanine, tyrosine, and valine, were significantly consumed during the first 12 days. This extensive nutrient depletion occurred despite cells being diluted to 0.5 × 10^6 cells/mL every second day according to standard protocols.
Metabolic Reprogramming During Expansion
The research revealed distinct phases of metabolic reprogramming during CAR T cell expansion. Flow cytometry confirmed expected activation patterns, with early activation marker CD69 expressed after 24 hours, followed by later markers including CD25, CD127, CD27, and PD-1 on day 7.
The metabolic data showed CAR T cells transition from oxidative phosphorylation to aerobic glycolysis during activation (days 1-7), with the glycolytic surge on day 7 coinciding with maximal cellular proliferation and activation marker expression. A particularly striking metabolic shift occurred around days 10-12, characterized by dramatic changes in glucose utilization and amino acid consumption.
"This sharp metabolic shift was partly cooperated in the proliferation data which revealed a slow linear increase days 3-10, followed by a sharp rise day 10-12 and followed by a subsequent decline days 13-15," the study reported.
Implications for Manufacturing Optimization
The findings highlight potential improvements for CAR T cell manufacturing protocols. The apparent rate constant for glycolytic conversion showed a significant 4.6-fold decrease from day 7 to day 14, with values of (5.278 ± 0.001) × 10^-5 s^-1 and (1.146 ± 1.022) × 10^-5 s^-1 respectively (p = 0.016).
The research suggests that prolonged glucose starvation during the first 10 days of culture could induce metabolic stress, potentially impairing CAR T cell expansion and functional persistence. "Glucose deprivation was shown to impair T cell activation and reduce cytokine production, thereby limiting T cell effector function," the authors noted.
Clinical Relevance and Future Applications
The study used anti-CD19 (search) CAR T cells with 4-1BB (search) co-stimulatory domains, representing clinically relevant constructs. Importantly, the research found comparable glycolytic flux between regular T cells and CAR T cells, suggesting that CAR integration did not substantially impact overall metabolic state.
The metabolic profiling approach could enable dynamic, tailored nutrient feeding strategies that align with evolving metabolic demands during expansion. The researchers propose implementing bioreactor systems with controlled nutrient delivery and waste removal to mitigate nutrient depletion and enhance final product quality.
While the study focused on in vitro expansion, the findings have implications for in vivo CAR T cell function. The tumor microenvironment remains metabolically hostile, characterized by nutrient depletion, hypoxia, and acidosis, conditions that would likely alter metabolic kinetics and suppress glycolytic activity in infused CAR T cells.
The combination of hyperpolarized NMR with traditional metabolomics provides complementary insights that could advance quality control during CAR T cell manufacturing, potentially improving therapeutic outcomes for patients with hematological cancers.